These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


691 related items for PubMed ID: 25812601

  • 1. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E, Deroma L, Bembi B, Deegan P, Hollak C, Weinreb NJ, Cox TM.
    Cochrane Database Syst Rev; 2015 Mar 27; 2015(3):CD010324. PubMed ID: 25812601
    [Abstract] [Full Text] [Related]

  • 2. Velaglucerase alfa for the management of type 1 Gaucher disease.
    Morris JL.
    Clin Ther; 2012 Feb 27; 34(2):259-71. PubMed ID: 22264444
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy results of switch from imiglucerase to velaglucerase alfa treatment in patients with type 1 Gaucher disease.
    Elstein D, Mehta A, Hughes DA, Giraldo P, Charrow J, Smith L, Shankar SP, Hangartner TN, Kunes Y, Wang N, Crombez E, Zimran A.
    Am J Hematol; 2015 Jul 27; 90(7):592-7. PubMed ID: 25776130
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Enzyme replacement therapy for infantile-onset Pompe disease.
    Chen M, Zhang L, Quan S.
    Cochrane Database Syst Rev; 2017 Nov 20; 11(11):CD011539. PubMed ID: 29155436
    [Abstract] [Full Text] [Related]

  • 6. Development of a panel of highly sensitive, equivalent assays for detection of antibody responses to velaglucerase alfa or imiglucerase enzyme replacement therapy in patients with Gaucher disease.
    Séllos-Moura M, Barzegar S, Pan L, Shi P, Oommen S, Durant J, Ruiz JA.
    J Immunol Methods; 2011 Oct 28; 373(1-2):45-53. PubMed ID: 21846471
    [Abstract] [Full Text] [Related]

  • 7. Taliglucerase alfa: safety and efficacy across 6 clinical studies in adults and children with Gaucher disease.
    Zimran A, Wajnrajch M, Hernandez B, Pastores GM.
    Orphanet J Rare Dis; 2018 Feb 23; 13(1):36. PubMed ID: 29471850
    [Abstract] [Full Text] [Related]

  • 8. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease.
    Ben Turkia H, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Ben Dridi MF, Gupta N, Kishnani PS, Sureshkumar EK, Wang N, Crombez E, Bhirangi K, Mehta A.
    Am J Hematol; 2013 Mar 23; 88(3):179-84. PubMed ID: 23400823
    [Abstract] [Full Text] [Related]

  • 9. A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM, Petakov M, Giraldo P, Rosenbaum H, Szer J, Deegan PB, Amato DJ, Mengel E, Tan ES, Chertkoff R, Brill-Almon E, Zimran A.
    Blood Cells Mol Dis; 2014 Dec 23; 53(4):253-60. PubMed ID: 24950666
    [Abstract] [Full Text] [Related]

  • 10. Long-term velaglucerase alfa treatment in children with Gaucher disease type 1 naïve to enzyme replacement therapy or previously treated with imiglucerase.
    Smith L, Rhead W, Charrow J, Shankar SP, Bavdekar A, Longo N, Mardach R, Harmatz P, Hangartner T, Lee HM, Crombez E, Pastores GM.
    Mol Genet Metab; 2016 Feb 23; 117(2):164-71. PubMed ID: 26043810
    [Abstract] [Full Text] [Related]

  • 11. Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase.
    Pastores GM, Shankar SP, Petakov M, Giraldo P, Rosenbaum H, Amato DJ, Szer J, Chertkoff R, Brill-Almon E, Zimran A.
    Am J Hematol; 2016 Jul 23; 91(7):661-5. PubMed ID: 27102949
    [Abstract] [Full Text] [Related]

  • 12. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase.
    Zimran A, Pastores GM, Tylki-Szymanska A, Hughes DA, Elstein D, Mardach R, Eng C, Smith L, Heisel-Kurth M, Charrow J, Harmatz P, Fernhoff P, Rhead W, Longo N, Giraldo P, Ruiz JA, Zahrieh D, Crombez E, Grabowski GA.
    Am J Hematol; 2013 Mar 23; 88(3):172-8. PubMed ID: 23339116
    [Abstract] [Full Text] [Related]

  • 13. A multicenter, open-label extension study of velaglucerase alfa in Japanese patients with Gaucher disease: Results after a cumulative treatment period of 24months.
    Ida H, Tanaka A, Matsubayashi T, Murayama K, Hongo T, Lee HM, Mellgard B.
    Blood Cells Mol Dis; 2016 Jul 23; 59():140-7. PubMed ID: 27241455
    [Abstract] [Full Text] [Related]

  • 14. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G, Lombardo R, Di Francesco E, Parrinello L, Di Raimondo F, Fiumara A.
    J Med Case Rep; 2016 Nov 08; 10(1):315. PubMed ID: 27821156
    [Abstract] [Full Text] [Related]

  • 15. Long-term efficacy and safety results of taliglucerase alfa through 5years in adult treatment-naïve patients with Gaucher disease.
    Zimran A, Durán G, Giraldo P, Rosenbaum H, Giona F, Petakov M, Terreros Muñoz E, Solorio-Meza SE, Cooper PA, Varughese S, Alon S, Chertkoff R.
    Blood Cells Mol Dis; 2019 Sep 08; 78():14-21. PubMed ID: 27499018
    [Abstract] [Full Text] [Related]

  • 16. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability.
    Pastores GM, Rosenbloom B, Weinreb N, Goker-Alpan O, Grabowski G, Cohn GM, Zahrieh D.
    Genet Med; 2014 May 08; 16(5):359-66. PubMed ID: 24263462
    [Abstract] [Full Text] [Related]

  • 17. Enzyme replacement therapy for Anderson-Fabry disease.
    El Dib R, Gomaa H, Carvalho RP, Camargo SE, Bazan R, Barretti P, Barreto FC.
    Cochrane Database Syst Rev; 2016 Jul 25; 7(7):CD006663. PubMed ID: 27454104
    [Abstract] [Full Text] [Related]

  • 18. Open-label, expanded access study of taliglucerase alfa in patients with Gaucher disease requiring enzyme replacement therapy.
    Kuter DJ, Wajnrajch M, Hernandez B, Wang R, Chertkoff R, Zimran A.
    Blood Cells Mol Dis; 2020 May 25; 82():102418. PubMed ID: 32146279
    [Abstract] [Full Text] [Related]

  • 19. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM, Barnett NL, Kolodny EH.
    Clin Ther; 2005 Aug 25; 27(8):1215-27. PubMed ID: 16199246
    [Abstract] [Full Text] [Related]

  • 20. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: early Access Program results from Jerusalem.
    Elstein D, Altarescu G, Maayan H, Phillips M, Abrahamov A, Hadas-Halpern I, Tiomkin M, Zimran A.
    Blood Cells Mol Dis; 2012 Jan 15; 48(1):45-50. PubMed ID: 22047948
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 35.